
A-620223 is a PARP-1 ингибитор with a Ki of 8 nM against PARP-1 and EC50 of 3 nM in a whole клетка assay. A-620223 demonstrates good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with Temozolomide (TMZ) and in an MX-1 breast xenograph model in combination with Cisplatin. A-620223 can be used for the studies of melanoma and breast cancer.
A-620223 is a PARP-1 inhibitor with a Ki of 8 nM against PARP-1 and EC50 of 3 nM in a whole cell assay. A-620223 demonstrates good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with Temozolomide (TMZ) and in an MX-1 breast xenograph model in combination with Cisplatin. A-620223 can be used for the studies of melanoma and breast cancer.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.